Humans have forced cod to shrink in size by half since 1990s, scientists find
Excessive fishing has forced Baltic cod to undergo genetic changes that have halved their size over the past 30 years, a new study has found.
The research, published in the journal Science Advances, is the first to show that decades of overfishing and environmental change can profoundly alter the genetic make-up of a fully marine species.
Baltic cod once measured more than a meter long and weighed up to 40kg, forming the backbone of the region's fishery. In the last three decades, however, the species has shrunk so much that even a full-grown cod can fit neatly on a dinner plate.
'For the first time in a fully marine species, we have provided evidence of evolutionary changes in the genomes of a fish population subjected to intense exploitation, which has pushed the population to the brink of collapse,' lead author Kwi Young Han said.
Researchers examined an archive of ear stones from 152 overexploited Eastern Baltic cod, Gadus morhua, caught in the Bornholm Basin between 1996 and 2019. The ear stones record annual growth in some fish species, similar to tree rings, making them valuable timekeepers.
They specifically looked into the growth trends of the cod over 25 years of heavy fishing and compared the changes with genetic alterations found in the species at the full genome level.
The study revealed a '48 per cent decrease in asymptotic body length' of the cod from 1996 to 2019, with indications that the species had evolved due to human interference.
Genetic variations in the cod associated with body growth showed signs of 'directional selection', researchers pointed out.
Some structural changes in the genome seemed to indicate environmental adaptation, hinting the "shrinking" had a genetic basis tied to human activity.
"Selective overexploitation has altered the genome of Eastern Baltic cod," Dr Han explained. "We see this in the significant decline in average size, which we could link to reduced growth rates.'
The study found the genomes of fast-growing cod differed systematically from slow growers, with the fast growers nearly disappearing from the Baltic.
"When the largest individuals are consistently removed from the population over many years, smaller, faster-maturing fish gain an evolutionary advantage," Thorsten Reusch, another author of the study, said. "What we're observing is evolution in action, driven by human activity. This is scientifically fascinating, but ecologically deeply concerning.'
The new research calls for conservation policies to look into the adaptive potential of marine species.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
3 hours ago
- The Guardian
Beastly Britain by Karen R Jones review – how animals shaped British identity
When newts go a-wooing, sometime in the spring, their signature move is the handstand. Girl newts cluster round to watch, while the boy newts flip on to their creepily human hands and shake their tails in the air. The waggiest newt is the winner, although the actual act of love is a strictly no-contact sport. The male deposits a packet of sperm on an underwater leaf for the female to collect and insert into her own reproductive tract. The whole business is best thought of, says Karen R Jones, as a 'sexually charged game of pass-the-parcel'. This kind of anthropomorphising often strikes naturalists as unscientific or even downright distasteful. But Jones is an environmental historian and her methodology allows, indeed impels, her to start from the principle that Britain's human and animal populations are culturally entwined. Consequently, we cannot 'see' a fox, hedgehog or newt without bringing to it a rich stew of presumptions and fantasy, drawn from childhood picturebooks, out-of-date encyclopedias and, in my case, the 1970s TV classic Tales of the Riverbank, in which small critters say funny things in the West Country burr of . This pre-knowing can have a radical impact on the chances of a particular species flourishing or going under. Take hedgehogs, which, Jones tells us in this beautifully written book, have been in Britain for the last 15m years. They witnessed the extinction of the woolly mammoth and saw the first humans arrive in Europe. It was at this point that they started to pick up a reputation for general malevolence. Bandit-like, hedgehogs were reputed to sneak into human settlements at night and steal poultry eggs (true) and suck the udders of sleeping cows (almost certainly false). Their ability to munch on toxic toads without getting sick (true) and willingness to ferry any witch who had lost her broomstick (surely very uncomfortable) confirmed that hedgehogs had gone over to the dark side. No wonder that killing them counted as a public service: the records of one Cheshire village show 8,585 hedgehogs destroyed over a 35-year period in the late 1600s. How different from today, when the hedgehog routinely tops those 'Britain's favourite animal' polls. Now we build shelters for them in our gardens and worry about how they will fare when crossing the road. This radical shift of opinion, says Jones, can be traced back to one hugely popular book, Beatrix Potter's The Tale of Mrs Tiggy-Winkle. Mrs Tiggy-Winkle is an industrious washerwoman who keeps her neighbours, including Peter Rabbit and his signature blue coat, spick and span. The influence of Potter's 1905 classic has been so enduring that, when a charity was set up in 1983 to care for injured hedgehogs, it was obvious what its name should be. These days, Tiggywinkles is the largest wildlife hospital in the world. Beastly Britain is full of stories like this, which take an everyday animal – newt, hedgehog, pigeon, sheep, flea – and map out both its physical life (a matter of burrows, breeding cycles and flight paths) as well as its cultural traces, which concern legend, loathing and desire. Often these two kinds of knowing collide in startling ways. Take sheep, which are mostly seen as 'white noise in the countryside', bland and bleating and only good for counting yourself to sleep. In fact, Jones reveals, they are crackingly clever, able to recognise the faces of up to 50 of their sheep-friends, not to mention their human guardians. The revelations keep on coming. For instance, that we are still living among dinosaurs. The next time a pigeon swoops down to steal a chip, take a close look at its scaly, reptilian feet. They are the legacy of the Archaeopteryx, a winged dinosaur the size of a raven, with a bony tail, flight feathers and an ability to glide over short distances. Less persuasive, though even more intriguing, is the possibility that a pod of plesiosaurs still bobs off the Devon and Cornwall coast. How else to account for the string of sightings of a giant grey sea snake, with a long neck, snakey head and vicious tusks? The rational part of us knows that this sea monster is likely to be a basking shark or a giant piece of flotsam. Our dreaming part longs for it to be a remnant from ancient times, what Jones calls a 'proximate peculiar', that refuses to quite come into view. Beastly Britain by Karen R Jones is published by Yale (£20). To support the Guardian, order your copy at Delivery charges may apply.
Sky News
7 hours ago
- Sky News
'Life-changing' drug for teenager who lost mother to genetic condition
A teenager who lost her mother, aunt and uncle to a genetic condition is the first person in Europe to receive a "life-changing" drug. Mary Catchpole, 19, from Great Yarmouth, suffers from a rare inherited disorder called activated PI3-Kinase delta syndrome (APDS), which leaves people with a significantly weakened immune system. The condition was passed down by her mother's side of the family, with her mother Sarah dying aged 42 in 2018, while her aunt Helen died aged 12, her uncle Edward when he was 39 and her grandmother Mary when she was 48. APDS patients are vulnerable to repeated infections, causing them to face a lifetime of antibiotics and immunoglobulin replacement therapy to prevent infections and organ damage, and a bone marrow or stem cell transplant - until now. A new drug called leniolisib (Joenja) is a simple tablet taken twice a day and is the first ever targeted treatment for APDS. Ms Catchpole, who is the first person in Europe to receive the medicine after it was made available on the NHS, said taking the new drug is "life-changing" as it means she can leave behind huge amounts of medication. "I was diagnosed with APDS aged seven and it's had a big effect on my life. I had lots of cannulas when I was younger and lots of hospital trips," she said. "I had a permanent line in the side of my body when I was younger, which they put medicine in regularly at the hospital." Ms Catchpole added that she wasn't allowed to do much physical activity, including dancing, which she's "always loved to do". "It has been hard," said the teaching assistant, who lives with her father Jimmy, 64, and her brother Joe, 20, who does not have APDS. The condition was identified by Cambridge researchers in 2013, with Ms Catchpole's family playing a key role in its discovery, as her mother and uncle were both patients at Addenbrooke's Hospital and were offered DNA sequencing to find out whether there was a genetic cause for their immunodeficiency. The researchers found a change in their genes that increased activity of an enzyme called PI3-Kinase delta, meaning this enzyme is effectively "switched on" all the time, preventing immune cells from fighting infection. Professor Sergey Nejentsev, from the University of Cambridge, who led the research that discovered APDS, said: "As soon as we understood the cause of APDS, we immediately realised that certain drugs could be used to inhibit the enzyme that is activated in these patients." The new drug works by inhibiting the PI3-Kinase delta enzyme, effectively normalising the immune system of the patient. "This new drug will make a huge difference to people living with APDS," Dr Anita Chandra, consultant immunologist at Addenbrooke's and affiliated assistant professor at the University of Cambridge, said. Ms Catchpole says she can now look to the future with optimism and lead a normal life. "I really want to become a dance teacher," she said. "I absolutely love my current job as a teaching assistant but I'd also like to go on some adventures as well. I've always felt different so it will be nice to feel like I belong." There are between 40 and 50 people in England who are known to have APDS.
BBC News
10 hours ago
- BBC News
New drug offers potential cure for ultra rare inherited condition
A teenager from Norfolk has become the first patient in Europe to be given a newly licensed treatment which could potentially cure her life-threatening, inherited Catchpole, 19, lost her mother, grandmother and several other relatives to the rare condition which affects the immune system, reducing her ability to fight infections."This treatment has brought me hope and joy," Mary told BBC News: "I feel like I can do anything, but it is bittersweet because my family members passed away before they could benefit."The newly licensed drug, leniolisib, is the first targeted treatment for her condition, Activated PI3-kinase Delta Syndrome or APDS. Not only is Mary the first patient to benefit from the drug but her family played a key role in research leading to the discovery of the ultra-rare was identified in 2013 by researchers at the University of Cambridge and clinicians at Addenbrooke's hospital who found a faulty gene carried by several members of Mary's Anita Chandra, consultant immunologist at Addenbrooke's Hospital and Affiliated Assistant Professor at the University of Cambridge said: "It is incredible to go from the discovery of a new disease in Cambridge to a treatment being approved and offered on the NHS, within the space of 12 years." Mary's father Jimmy said: "We just wanted to help, not just for our own sakes, but we'd heard there were other rare cases. "My wife volunteered for trials and, when Mary got old enough, she did too."Mary's mother Sarah died aged 43, her aunt aged 12, her uncle aged 39 and her grandmother at of Mary's cousins was successfully treated as a child with a bone marrow transplant, but these carry significant who was 12 when her mother died, told us: "It was always a fear that I would die young too but with this medication, I know I can have a longer life, which is what she wanted."In APDS, an enzyme produced in the body is "switched on" all the time, disrupting the development of white blood cells and causing the immune system to be with the condition are vulnerable to repeated lung infections which can lead to irreversible damage. It can cause organs and lymph nodes to swell, and the body's immune system to attack healthy tissue. Patients are also at risk of lymphoma, a cancer which affects a type of white blood drug, branded Joenja, is taken twice daily as tablets, and works by blocking the enzyme, allowing the immune system to work told the BBC: "This is something I have dreamt about since Mary was first diagnosed; it is giving her the chance to live a normal life."Mary suffered regular chest infections as a child and has been repeatedly treated with intravenous antibiotics, nebulisers and immunoglobulin replacement has been taking the leniolisib tablets for less than a month but has already stopped some other Chandra, who is Mary's consultant and has treated several other family members, said the drug was a "potential cure". Mary is rethinking about how she will live in future: "I want to go on more adventures and take risks because all I've ever known is medication, needles, and hospital appointments, whereas now I can find out who I truly am."The faulty gene is carried on the maternal line so there is a 50:50 chance it will be passed to affected women's children. Mary said she would like to become a dance teacher, while continuing her work as a teaching assistant. She said she had been cautious around people because of the risk of infection but no longer felt Sergey Nejentsev from the University of Cambridge who led the research that discovered APDS said: "As soon as we understood the cause of APDS, we immediately realised that certain drugs could be used to inhibit the enzyme that is activated in these patients. Leniolisib does precisely that. I am delighted that we finally have a treatment which will change the lives of APDS patients."Leniolisib has a list price of £352,000 a year, but was approved as cost effective by the health regulator NICE after the NHS negotiated a substantial, confidential estimates the drug could benefit up to 50 patients over the age of 12 in James Palmer, NHS England's Medical Director for Specialised Commissioning, said: "This treatment could be life-changing for those affected by this debilitating genetic disorder, and this important step forward is another example of the NHS's commitment to offering access to innovative medicines for those living with rare conditions."
